Generic Vyndamax Availability
Last updated on Nov 6, 2024.
See also: Generic Vyndaqel
Vyndamax is a brand name of tafamidis, approved by the FDA in the following formulation(s):
VYNDAMAX (tafamidis - capsule;oral)
-
Manufacturer: FOLDRX PHARMS
Approval date: May 3, 2019
Strength(s): 61MG [RLD]
Has a generic version of Vyndamax been approved?
No. There is currently no therapeutically equivalent version of Vyndamax available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Vyndamax. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Patent 7,214,695
Patent expiration dates:
- December 19, 2025✓✓
- December 19, 2025
-
Patent 7,214,696
Patent expiration dates:
- December 19, 2025✓
- December 19, 2025
-
Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole
Patent 9,770,441
Issued: September 26, 2017
Inventor(s): Girard Kevin Paul & Jensen Andrew J. & Jones Kris Nicole
Assignee(s): Pfizer Inc.The present invention relates to solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole and to methods for their preparation. The invention is also directed to pharmaceutical compositions containing at least one solid form and to the therapeutic or prophylactic use of such solid forms and compositions.
Patent expiration dates:
- August 31, 2035✓✓✓
- August 31, 2035
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- May 3, 2024 - NEW CHEMICAL ENTITY
- May 3, 2026 - TREATMENT OF THE CARDIOMYOPATHY OF WILD TYPE OR HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS (ATTR-CM) IN ADULTS TO REDUCE CARDIOVASCULAR MORTALITY AND CARDIOVASCULAR-RELATED HOSPITALIZATION
More about Vyndamax (tafamidis)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (3)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: transthyretin stabilizers
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
